A Phase 3 interventional study of Desmopressin Injectable Solution and Tranexamic Acid Injectable Product in Chronic Kidney Diseases, Acute Kidney Injury and Bleeding, sponsored by Hamilton Health Sciences Corporation. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Hamilton Health Sciences Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 215 studies in Renal Insufficiency, Chronic with a site in Canada — 37 open to participants now, 61 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Canada.
Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, this one is the 112th largest by planned enrollment of the 173 interventional ones that give a count, is one of 14 that started in 2025, is one of 59 in phase 3, reaches primary completion later than 30 of the 60 other live ones, and was the 174th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →37 of the 215 studies in Renal Insufficiency, Chronic with a site in Canada are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Canada, United States, Argentina and 24 more countries
Ages 18–99
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 34 more countries
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
215 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 35 · Phase 3 61 · Phase 4 15
First in 2002; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 195 across the 173 interventional studies, 500 across the 41 observational. Of the 143 that completed or were terminated, 58 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 215 have an industry lead sponsor. The 10 most frequent:
Hamilton Health Sciences Corporation is the lead sponsor of 242 studies on the registry; 38 are open to participants now.
Hamilton Health Sciences Corporation has 4 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
14 of the studies in Renal Insufficiency, Chronic with a site in Canada that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT06337838Phase 3Hamilton Health Sciences CorporationBleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial | 2027-02 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 14 to your calendar (.ics) → With an account.
Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.
Perioperative administration of TXA reduces bleeding risk in surgical patients. However, large clinical trials have excluded patients with advanced kidney disease, so the benefits remain uncertain in this population, and there is potential for harm. The benefit of desmopressin, which is purported to more directly address the defect of primary hemostasis believed important in severe kidney disease more directly than TXA, has not been examined in adequate randomized control trials (RCTs). Both medications are generic and have been available for many years. To convincingly test these medications in patients with severe kidney disease, large, global trials are required. This pilot-phase trial will 1) inform the feasibility and design of a large international trial to evaluate the efficacy and safety of TXA and desmopressin in patients with advanced kidney disease undergoing noncardiac surgery, 2) provide preliminary data regarding the efficacy and safety of TXA and desmopressin in people with advanced kidney disease having noncardiac surgery, and 3) provide pharmacokinetic data to inform dose selection.
Eligibility criteria specific to the tranexamic acid (TXA) factorial component of trial Inclusion Criteria:
One of either:
1.1. \<25 ml/min/1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days;
Exclusion Criteria:
Eligibility criteria specific to the desmopressin factorial component of trial
Inclusion criteria:
1. Included in the TXA factorial.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with estimated glomerular filtration rate (eGFR) \<25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis. Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin intervention group will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes.
Drug: Desmopressin Injectable Solution · Drug: Tranexamic Acid Injectable Product
Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with eGFR \<25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis. Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes.
Drug: Tranexamic Acid Injectable Product · Other: Placebo
Within 20 minutes preceding anticipated skin incision, patients will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes. Patients will not receive prophylactic tranexamic acid. Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group.
Drug: Desmopressin Injectable Solution · Other: Placebo
Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group. Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes.
Other: Placebo
Intravenous desmopressin, 20 mcg, single dose administration.
Also known as: DDAVP
Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.
Also known as: Cyklokapron
Intravenous 0.9% saline solution
Rate of recruitment
A rate of 0.25 patients per study site per week
Time frame: Through study completion, an average of 1.5 years
Receipt of the allocated study drug within 1 hour before start of surgery for the tranexamic acid factorial
Account of whether the patient began to receive study drug for the TXA factorial within an hour before skin incision. Target ≥80% of participants
Time frame: Day of surgery
Receipt of the allocated study drug within 1 hour before start of surgery for the desmopressin factorial
Account of whether the patient began to receive study drug for the desmopressin factorial within an hour before skin incision. Target ≥80% of participants
Time frame: Day of surgery
Completion of 30-day follow-up
Account of whether the patient or their next-of-kin could be contacted and completed the 30-day post-randomization assessment. Target ≥80% of participants
Time frame: 30 days after randomization
Bleeding Independently Associated with Mortality after noncardiac Surgery (BIMS)
Number of patients who experience BIMS
Time frame: 30 days after randomization
Bleeding Score
10-category ordinal score. Minimum scores mean a better outcome. 0 denotes no bleeding or bleeding in which the nadir hemoglobin is ≥70 g/L, no red blood transfusion was given, no reoperation for reasons of bleeding occurred, and there was no death imminently or directly caused by bleeding. 1. denotes bleeding and post-operative hemoglobin \<70 g/L or 1 unit of blood (red blood cells or whole blood) transfused. 2. denotes bleeding and 2 units transfused. 3. denotes bleeding and 3 units transfused. 4. denotes bleeding and 4 units transfused 5. denotes bleeding and 5 units transfused. 6. denotes bleeding and 6 units transfused. 7. denotes bleeding and 7 units transfused. 8. denotes bleeding and 8 or more units of blood transfused. 9. denotes reoperation for reasons of bleeding. 10. denotes death imminently or directly caused by bleeding.
Time frame: 30 days after randomization
Reoperation for reasons of bleeding
Number of patients who return to the operating room for surgical management of suspected documented bleeding
Time frame: 30 days after randomization
Blood (red blood cells or whole blood) transfused
Number of units of blood transfused.
Time frame: 30 days after randomization
Blood (red blood cells or whole blood) transfused
Number of units of blood transfused.
Time frame: Up to and including postoperative day 3 after surgery
Any blood transfusion (red blood cells or whole blood)
Number of units of blood transfused.
Time frame: 30 days after randomization
Any blood transfusion (red blood cells or whole blood)
Number of units of blood transfused.
Time frame: Up to and including postoperative day 3
Lowest measured hemoglobin concentration
The mean absolute difference for continuous outcomes using linear regression with treatment allocation
Time frame: 30 days after randomization
Most recent hemoglobin concentration
The mean absolute difference for continuous outcomes using linear regression with treatment allocation
Time frame: 30 days after randomization
Death
Number of patients who die of any cause
Time frame: 30 days after randomization
Major arterial and venous thrombosis
(i.e., composite of myocardial injury after noncardiac surgery \[MINS\], stroke, peripheral arterial thrombosis, dialysis vascular access thrombosis requiring anticoagulation or intervention, and symptomatic venous thromboembolism)
Time frame: 30 days after randomization
Myocardial Injury after Noncardiac Surgery (MINS)
Number of patients who experience MINS
Time frame: 30 days after randomization
Myocardial Injury after Noncardiac Surgery (MINS) that meets criteria for myocardial infarction
Number of patients who experience MINS that meets criteria for myocardial infarction (based on the Fourth Universal Definition of myocardial infarction)
Time frame: 30 days after randomization
MINS that is an isolated ischemic troponin elevation
Number of patients who experience MINS that is an isolated ischemic troponin elevation
Time frame: 30 days after randomization
Stroke
Number of patients experiencing a stroke
Time frame: 30 days after randomization
Non-hemorrhagic stroke
Number of patients who experience a non-hemorrhagic stroke
Time frame: 30 days after randomization
Hemorrhagic stroke
Number of patients who experience a hemorrhagic stroke
Time frame: 30 days after randomization
Peripheral arterial thrombosis
Number of patients who experience a peripheral arterial thrombosis
Time frame: 30 days after randomization
Thrombosis of arteriovenous fistula or graft
Number of patients who have thrombosis of arteriovenous fistula or graft
Time frame: 30 days after randomization
Symptomatic proximal venous thromboembolism
Number of patients who experience symptomatic proximal venous thromboembolism
Time frame: 30 days after randomization
Symptomatic pulmonary embolism
Number of patients who experience a symptomatic pulmonary embolism
Time frame: 30 days after randomization
Symptomatic proximal leg or arm deep venous thrombosis (DVT)
Number of patients who experience a symptomatic proximal leg or arm DVT
Time frame: 30 days after randomization
Non-fatal cardiac arrest
Number of patients who experience non-fatal cardiac arrest
Time frame: 30 days after randomization
Coronary revascularization procedure
Number of patients who undergo coronary revascularization procedure
Time frame: 30 days after randomization
Clinically important atrial fibrillation or flutter
Number of patients who experience clinically important atrial fibrillation or flutter
Time frame: 30 days after randomization
Acute heart failure or clinically important volume overload
Number of patients who experience acute heart failure or clinically important volume overload.
Time frame: 30 days after randomization
Acute kidney injury (for patients not receiving dialysis before surgery)
Number of patients who experience an acute kidney injury
Time frame: 30 days after randomization
New start of dialysis
Number of patients who require new start of dialysis
Time frame: 30 days after randomization
Seizure
Number of patients who experience a seizure
Time frame: 30 days after randomization
Clinically significant intraoperative hypotension
Number of patients who experience clinically significant intraoperative hypotension
Time frame: 30 days after randomization
Clinically significant postoperative hypotension
Number of patients who experience clinically significant postoperative hypotension
Time frame: Up to and including the end of postoperative day 1
Sepsis
Number of patients who experience sepsis
Time frame: 30 days after randomization
Duration of surgery
The time from skin incision to closure, in minutes.
Time frame: 30 days after randomization
Receipt of platelets
Any transfusion of this blood product
Time frame: 30 days after randomization
Receipt of fibrinogen
Any transfusion of this blood product
Time frame: 30 days after randomization
Receipt of fresh frozen plasma
Any transfusion of this blood product
Time frame: 30 days after randomization
Receipt of cryoprecipitate
Any transfusion of this blood product
Time frame: 30 days after randomization
Receipt of recombinant Factor VIIa
Number of patients receiving recombinant factor VIIa
Time frame: 30 days after randomization
Receipt of prothrombin complex concentrate
Number of patients who receive prothrombin complex concentrate
Time frame: 30 days after randomization
Prescribed erythropoiesis stimulating agent
Number of patients receiving a weekly dose of erythropoiesis stimulating agent on prescription active at 30 days
Time frame: 30 days after randomization
Severe hyponatremia
Measured serum sodium concentration \<125 meq/L
Time frame: Up to and including the end of postoperative day 1
Duration of hospital stay after surgery
Cumulative number of nights spent in an acute care hospital
Time frame: Day of surgery and ending the day of discharge
Duration of critical care stay after surgery
Cumulative number of nights spent in an intensive care unit
Time frame: Day of surgery and ending the day of discharge
Delayed graft function after kidney transplantation
Receipt of dialysis
Time frame: Within 7 days following kidney transplantation
Persistent dialysis dependence
Participant continues to receive dialysis after surgery.
Time frame: 30 days after randomization
Incisional site pain severity
Rating of pain using the 10-point ordinal scale where 0 corresponds to no pain and 10 corresponds to the worst pain imaginable.
Time frame: 30 days after randomization in the last 24 hours
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 20 months after the start.
Of 41 non-industry phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 69. This study's planned 20 months is below that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deamino Arginine Vasopressin · Tranexamic Acid
Renal Insufficiency, Chronic →
Hamilton Health Sciences Corporation →